Summary

for people ages 18 years and up (full criteria)
at Orange, California and other locations
study started
estimated completion

Description

Summary

Evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.

Official Title

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Details

Evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

Keywords

Advanced CancerMetastatic CancerMalignant Neoplastic DiseaseKRASNSCLCColorectal CancerColon CancerNeoplasm MetastasisNeoplasmsMRTX849

Eligibility

You can join if…

Open to people ages 18 years and up

  • Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
  • Unresectable or metastatic disease
  • Standard treatment is not available or patient declines
  • Adequate organ function

You CAN'T join if...

  • Active brain metastases
  • History of intestinal disease or major gastric surgery or inability to swallow oral medications
  • Other active cancer

Locations

  • University of California, Irvineaccepting new patients
    OrangeCalifornia92868United States
  • South Texas Accelerated Research Therapeuticsaccepting new patients
    San AntonioTexas78229United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Mirati Therapeutics Inc.
ID
NCT03785249
Phase
Phase 1/2
Study Type
Interventional
Last Updated